I
Intensity Therapeutics, Inc. (INTS)
NCM – Real Time Price. Currency in USD
4.88
-0.12 (-2.40%)
At close: May 12, 2026, 4:00 PM EDT
4.82
-0.06 (-1.23%)
After-hours: May 12, 2026, 6:57 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.88
-0.12 (-2.40%)
At close: May 12, 2026, 4:00 PM EDT
4.82
-0.06 (-1.23%)
After-hours: May 12, 2026, 6:57 PM EDT
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
| Name | Position |
|---|---|
| Mr. James M. Ahlers | Executive Vice President of Corporate Finance |
| Mr. John Wesolowski C.P.A., M.B.A. | Principal Accounting Officer & Controller |
| Mr. Joseph Talamo C.P.A., M.B.A. | Chief Financial Officer |
| Mr. Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, CEO & Chairman of the Board |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | intensity-20260507.htm |
| 2026-05-07 | 10-Q | intensity-20260331.htm |
| 2026-04-30 | DEF 14A | intensity-20260430.htm |
| 2026-03-27 | 8-K | intensity-20260327.htm |
| 2026-03-23 | 8-K | intensity-20260323.htm |
| 2026-03-06 | 8-K | intensity-20260305.htm |
| 2026-03-05 | 8-K | intensity-20260305.htm |
| 2026-02-13 | 8-K | intensity-20260213.htm |
| 2026-01-23 | S-8 | forms-8january2026.htm |
| 2025-12-05 | 8-K | intensity-20251204.htm |